Drugs / Y-6
last change Dec 2025 re-read 2 minutes ago

Y-6

also known as Y-6 sublingual tablets
Developed for
ischemic stroke · large artery stroke
Investigated by
Beijing Tiantan Hospital · Neurodawn Pharmaceutical Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06138834 Nov 2023 → Nov 2024 ischemic stroke, large artery stroke Beijing Tiantan Hospital Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Y-6 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06138834
Known as Y-6 sublingual tablets “To investigate the efficacy and safety of Y-6 sublingual tablets (cilostazol and dexborneol) compared with a placebo in the treatment of patients with acute ischaemic stroke...” PMID 40246318 Dec 2025